Covista Inc. (CVSA) FY2025 10-K Annual Report
Covista Inc. (CVSA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 7, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Covista Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Provider of postsecondary education with focus on medical and healthcare programs
- • Emphasis on regulatory compliance risks impacting Title IV funding and clinical placement limitations for medical schools
Management Discussion & Analysis
- • No revenue or profit figures disclosed in the MD&A section
- • Key risk: potential fines, debt discharge liabilities, or suspension from Title IV programs due to "substantial misrepresentation" claims
Risk Factors
- • Regulatory risk from U.S. Department of Education (ED) Borrower Defense to Repayment rules affecting Title IV loan obligations recovery
- • Geopolitical exposure to U.S. federal and state investigations, risking Title IV program eligibility restrictions across multiple institutions
Covista Inc. FY2025 Key Financial MetricsXBRL
Revenue
$1.8B
▲ +12.9% YoY
Net Income
$237M
▲ +73.3% YoY
Operating Margin
19.1%
▲ +540bp YoY
Net Margin
13.3%
▲ +463bp YoY
ROE
16.5%
▲ +655bp YoY
Total Assets
$2.8B
▲ +0.4% YoY
EPS (Diluted)
$6.18
▲ +82.3% YoY
Operating Cash Flow
$338M
▲ +14.2% YoY
Source: XBRL data from Covista Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Covista Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.